Status:
WITHDRAWN
A Pilot Study of IRE for Resectable Pancreatic Cancer
Lead Sponsor:
University of Saskatchewan
Collaborating Sponsors:
Saskatchewan Health Research Foundation
Conditions:
Pancreatic Adenocarcinoma Resectable
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The operation to remove certain pancreatic cancers (Whipple procedure), even in 2017, remains one of the most complicated surgeries done in the abdomen. It carries a 50% chance of a complication, even...
Detailed Description
* Subjects will receive a general anesthetic and will undergo a midline laparotomy and a careful inspection to ensure no distant metastases are obvious in the peritoneal cavity. * Ultrasound-guided IR...
Eligibility Criteria
Inclusion
- Biopsy-proven pancreatic adenocarcinoma of the head of the pancreas.
- Age 18 to 75.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Pregnancy
- Subjects who are medically unfit to receive a general anesthetic.
- Patients with cardiac arrhythmia other than rate controlled atrial fibrillation.
- Tumors greater than 3 cm.
- Unresectable or locally advanced pancreatic cancer.
- Patients with a high suspicion for lymph node metastasis or peripancreatic pathologic (\> 1 cm) lymph nodes on imaging.
- Metastatic pancreatic carcinoma, including unexpected peritoneal or liver metastases discovered at the time of laparotomy for planned IRE.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03337997
Start Date
October 1 2021
End Date
January 1 2025
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8